Alnylam Pharmaceuticals Inc. (Nasdaq: ALNY) of Cambridge said it will accelerate development of two lead drug candidates that offer the greatest commercial opportunity, and that it has discovered a novel method to monitor the activity of RNAi in blood samples and granted the first license to Isis Pharmaceuticals.

SOURCE